Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.

05 Aug 2020

Destiny Pharma - CEO Interview on Phase 2b trial and outlook - August 2020

Neil Clark updates that the FDA's decision to lower patient numbers in the ongoing trial will not dilute the quality of the outcome, but will save Destiny money and time - with completion expected this year.

At the same time, Covid-19 has filled hospitals highlighting again the signifcant dangers of post-operative infection given the ever increasing resistance of bacteria to antibiotics ('Superbugs').

Destiny's lead product XF-73 is aimed at preventing infection and Neil discusses commercial options for the group if the trial outcome is as hoped, and also updates on the rest of Destiny's pipeline in development. Video is 18 minutes long.

Return to Destiny Pharma

Register to be first

Get research on the companies that interest you straight to your inbox

Equity Development is a partner to successful companies looking to enhance their investor relations. Our top-rated analysts produce best in class investment research. Based in London, UK, we help our clients connect with investors via presentations and interviews.

Equity Development Limited 2nd Floor, Park House, 16-18 Finsbury Circus, London, EC2M 7EB

Website design & development by Breckenridge